Provided by Tiger Fintech (Singapore) Pte. Ltd.

Meiragtx Holdings Plc

7.25
-0.0100-0.14%
Post-market: 7.20-0.0499-0.69%16:21 EDT
Volume:305.29K
Turnover:2.25M
Market Cap:571.70M
PE:-3.43
High:7.50
Open:7.32
Low:7.25
Close:7.26
Loading ...

Press Release: MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Dow Jones
·
13 Mar

BRIEF-MeiraGTx collaborates with Hologen AI to expedite development of its Parkison's disease therapy, scale up manufacturing

Reuters
·
13 Mar

MeiraGTx Holdings Plc - to Receive $200 Million in Upfront Cash

THOMSON REUTERS
·
13 Mar

MeiraGTx Enters Into a Strategic Collaboration With Hologen AI to Expedite Phase 3 Development of Aav-Gad for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

THOMSON REUTERS
·
13 Mar

MeiraGTx Holdings Plc - to Retain 30% Ownership in Joint Venture

THOMSON REUTERS
·
13 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

MeiraGTx Holdings PLC expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

High Growth Tech Stocks In The United States Spotlighting Three Leaders

Simply Wall St.
·
26 Feb

MeiraGTx Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
24 Feb

MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release

Dow Jones
·
22 Feb

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

Reuters
·
22 Feb

MeiraGTx Shares up 4.3% on Positive Data From Genetic Eye Condition Treatment

THOMSON REUTERS
·
21 Feb

BUZZ-MeiraGTx rises on positive data from genetic eye condition treatment

Reuters
·
21 Feb

MeiraGTx Announces the Lancet Publication of Data Demonstrating the Efficacy of Raav8.hrkp.aipl1 for the Treatment of Leber Congenital Amaurosis 4 (Lca4) Retinal Dystrophy

THOMSON REUTERS
·
21 Feb

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

GlobeNewswire
·
21 Feb

MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions

Simply Wall St.
·
30 Jan

MeiraGTx Says FDA Grants Rare Pediatric Disease Designation to Eye Disorder Drug

MT Newswires Live
·
22 Jan

MeiraGTx Receives Rare Pediatric Disease Designation From FDA for Aav8-Rk-Retgc for the Treatment of Patients With Leber Congenital Amaurosis Due to Gucy2d Mutations

THOMSON REUTERS
·
22 Jan

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

GlobeNewswire
·
22 Jan